Onkos Surgical announced the completion of the 500th case utilizing its NanoCept Antibacterial Technology on the ELEOS Limb Salvage System.
Since receiving De Novo authorization in 2024, NanoCept Antibacterial Technology has been adopted by surgeons treating complex orthopaedic oncology and revision cases, where patient and procedural factors may elevate the risk of bacterial contamination. NanoCept is an antibacterial implant coating technology intended to mitigate bacterial contamination on the implant surface prior to implantation.
The milestone case was performed in Plano, TX by Dr. Cyrus Abbaschian, highlighting the continued integration of NanoCept into the ELEOS system across a growing number of institutions.
The ELEOS Limb Salvage System is designed to support surgeons in addressing complex bone loss and reconstruction challenges, with NanoCept offering an additional option to address bacterial contamination as part of a broader intraoperative protocol.
“The completion of our 500th NanoCept case with the ELEOS system reflects the growing adoption of this technology among surgeons treating some of the most complex orthopaedic conditions,” said Patrick Treacy, Founder and Chief Executive Officer of Onkos Surgical. “Since our De Novo authorization, our focus has been on expanding access to NanoCept in a thoughtful, evidence-driven way. We are proud to support surgeons like Dr. Abbaschian as they continue to advance patient care in this demanding field.”
Onkos Surgical announced the completion of the 500th case utilizing its NanoCept Antibacterial Technology on the ELEOS Limb Salvage System.
Since receiving De Novo authorization in 2024, NanoCept Antibacterial Technology has been adopted by surgeons treating complex orthopaedic oncology and revision cases, where patient and procedural factors...
Onkos Surgical announced the completion of the 500th case utilizing its NanoCept Antibacterial Technology on the ELEOS Limb Salvage System.
Since receiving De Novo authorization in 2024, NanoCept Antibacterial Technology has been adopted by surgeons treating complex orthopaedic oncology and revision cases, where patient and procedural factors may elevate the risk of bacterial contamination. NanoCept is an antibacterial implant coating technology intended to mitigate bacterial contamination on the implant surface prior to implantation.
The milestone case was performed in Plano, TX by Dr. Cyrus Abbaschian, highlighting the continued integration of NanoCept into the ELEOS system across a growing number of institutions.
The ELEOS Limb Salvage System is designed to support surgeons in addressing complex bone loss and reconstruction challenges, with NanoCept offering an additional option to address bacterial contamination as part of a broader intraoperative protocol.
“The completion of our 500th NanoCept case with the ELEOS system reflects the growing adoption of this technology among surgeons treating some of the most complex orthopaedic conditions,” said Patrick Treacy, Founder and Chief Executive Officer of Onkos Surgical. “Since our De Novo authorization, our focus has been on expanding access to NanoCept in a thoughtful, evidence-driven way. We are proud to support surgeons like Dr. Abbaschian as they continue to advance patient care in this demanding field.”
Copy to clipboard 
